GeneDx Holdings Corp. (WGS)
NASDAQ (NGS) NASDAQ (NGS) Primary Summary
GeneDx Holdings Corp. (WGS) Q3 2025 Earnings Call Transcript
GeneDx Holdings Corp. (NASDAQ:WGS ) Q3 2025 Earnings Call October 28, 2025 8:30 AM EDT Company Participants Sabrina Dunbar Katherine Stueland - President, CEO & Director Kevin Feeley - Chief Financial Officer Bryan Dechairo - Chief Operating Officer Conference Call Participants Subhalaxmi Nambi - Guggenheim Securities, LLC, Research Division Daniel Brennan - TD Cowen, Research Division Mark Massaro - BTIG, LLC, Research Division Tycho Peterson - Jefferies LLC, Research Division David Westenberg - Piper Sandler & Co., Research Division William Bonello - Craig-Hallum Capital Group LLC, Research Division Kyle Mikson - Canaccord Genuity Corp., Research Division Keith Hinton - Prime Executions, Inc., Research Division Presentation Operator Good day, and thank you for standing by. Welcome to the GeneDx Third Quarter 2025 Earnings Conference Call.
GeneDx's Blueprint For The Next Healthcare Revolution
GeneDx Holdings is transforming into a global genetic software leader, leveraging its vast database and recent Fabric Genomics acquisition. WGS achieved strong Q2 results: 49% revenue growth, 71% gross margin, positive cash flow, and raised full-year guidance, signaling accelerating adoption. The AAP's new recommendations and NIH funding position WGS for significant market expansion, with insurance coverage supporting sustainable, recurring revenue.
How GeneDX CEO Katherine Stueland is using AI to save lives
She started her career helping launch breakthrough treatments for HIV and cancer. Today, Katherine Stueland is leading GeneDx — a genetic testing company using genomic insights to diagnose rare diseases faster and more accurately than ever before.
GeneDx Holdings Corp. (WGS) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
What is the earnings per share?
When is the next earnings date?
Has GeneDx Holdings Corp. ever had a stock split?
GeneDx Holdings Corp. Profile
| Biotechnology Industry | Healthcare Sector | Katherine A. Stueland CEO | NASDAQ (NGS) Exchange | 81663L200 CUSIP |
| US Country | 1,000 Employees | - Last Dividend | 4 May 2023 Last Split | 4 Nov 2020 IPO Date |
Overview
GeneDx Holdings Corp. is a pioneering entity in the field of genomics, delivering a wide array of diagnostic and information services through its subsidiaries since its inception in 2017. Headquartered in Stamford, Connecticut, the company strides ahead with a robust commitment to enhancing healthcare through genomics. It stands out in the medical community for integrating advanced digital tools and artificial intelligence within its operations, which significantly boosts its capability to offer comprehensive health insights. The focus on pediatrics, rare diseases for both children and adults, as well as hereditary cancer screening, positions GeneDx Holdings Corp. as a key player in the advancement of personalized and precision medicine.
Products and Services
- Centrellis Health Intelligence Platform - An AI-driven platform that revolutionizes the way health data is used. Centrellis integrates digital tools and artificial intelligence, enabling researchers and scientists to efficiently ingest, process, and synthesize clinical and genomic data. This integration facilitates the delivery of comprehensive health insights, aiding in the advancement of personalized medicine and enhancing patient care outcomes.
- Genetic Diagnostic Tests - GeneDx Holdings Corp. offers an extensive range of genetic diagnostic tests aimed at identifying genetic disorders at an early stage. These tests are pivotal in detecting a variety of conditions, enabling healthcare providers to devise appropriate treatment and management plans tailored to the individual needs of patients.
- Screening Solutions - The company provides state-of-the-art screening solutions that play a crucial role in preemptive health care. These solutions are designed to detect potential health issues before they become serious, thereby enabling timely intervention and reducing the overall healthcare burden.
- Information Services - With a strong emphasis on pediatrics, rare diseases, and hereditary cancer screening, GeneDx Holdings Corp. extends comprehensive information services. These services are rooted in the latest research and innovations in genomics, offering invaluable support to both healthcare providers and patients in navigating complex health conditions and making informed decisions.
